Yu-Ning Wong, MD, MSCE

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Philadelphia Magazine 2009
Rising Star Under 40
Medical Oncology

Patient Stories from Fox Chase Patients Dr. Wong's
Patient Stories

  • Jesus Calderon - Clinical-Trials Patient Stories, Kidney Cancer Patient Stories
  • Richard Frantz - Bladder Cancer Patient Stories, Clinical-Trials Patient Stories
  • Jay Hyman - Clinical-Trials Patient Stories, Kidney Cancer Patient Stories
  • Lawrence James - Germ Cell Tumor Treatment Patient Stories
  • David Juall - Kidney Cancer Patient Stories
  • Chuck Leonard - Kidney Cancer Patient Stories
  • Robert Singer - Hormone Therapy for Prostate Cancer Patient Stories, Prostate Cancer Patient Stories
  • Andrew Steinmetz - Testicular Cancer Patient Stories
Dr Yu-Ning Wong


Associate Professor
Program Director, GU Medical Oncology Services

Meet other members of the

Genitourinary Cancer Patient Care Team

Clinical Expertise:

Prostate Cancer; Bladder Cancer; Kidney Cancer; Testicular Cancer


Internal Medicine, Oncology

Medical Education

Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, NJ;
Master of Science in Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA


Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, Pa.


Hematology and Medical Oncology, Fox Chase 
Cancer Center and Temple University Hospital, Philadelphia, PA;
Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA

Research Interests

Genitourinary Malignancies


Dr. Wong on My NCBI 

  1. Financial Concerns Among Cancer Patients About Participation In Clinical Trials Wong,Yu-Ning,, Schlucter,Mark,D, Albrecht,Terrance,L, Benson,Al,B, Buzaglo,Joanne,, et al.
    Journal of Clinical Oncology. Forthcoming; My Bibliography [journal]
  2. Randomized Trial of a Web-based Intervention to Address Barriers to Clinical Trials Meropol,Neal,J, Wong,Yu-Ning,, Albrecht,Terrance,L, Manne,Sharon,, Miller,Suzanne,M, et al.
    Journal of Clinical Oncology. Forthcoming; My Bibliography [journal]
  3. Adjuvant Chemotherapy Use and Healthcare Costs after the Introduction of Genomic Testing in Breast Cancer Epstein,Andrew,J, Wong,Yu-Ning,, Mitra,Nandita,, Vachani,Anil,, Hin,Sakhena,, et al.
    Journal of Clinical Oncology . Forthcoming; My Bibliography [journal]
  4. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. doi:
    10.1056/NEJMoa1503747. Epub 2015 Aug 5. PubMed [citation] PMID: 26244877, PMCID:
  5. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Aug 1. doi:pii: S0302-2838(15)00613-2. 10.1016/j.eururo.2015.07.009. [Epub ahead of print] PubMed [citation] PMID: 26238431
  6. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12. PubMed [citation] PMID: 24821881, PMCID: PMC4050203
  7. Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl. 2014 May-Jun;16(3):372-7. doi: 10.4103/1008-682X.125903.
    Review. PubMed [citation] PMID: 24759579, PMCID: PMC4023362
  8. Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012 Oct 1;30(28):3545-51. Epub 2012 Aug 27. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612. PubMed [citation] PMID: 22927525, PMCID: PMC3454772
  9. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol.
    2009 Jan 1;27(1):100-5. doi: 10.1200/JCO.2007.14.2042. Epub 2008 Dec 1. PubMed [citation] PMID: 19047295, PMCID: PMC2645095
  10. Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006 Dec 13;296(22):2683-93. Erratum in: JAMA. 2007 Jan 3;297(1):42. PubMed [citation] PMID: 17164454
  11. Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009 Oct;56(4):609-16. doi: 10.1016/j.eururo.2009.03.066. Epub 2009 Apr 1. PubMed [citation] PMID: 19368995, PMCID: PMC2791191
  12.  Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug 1;121(15):2586-93. doi:
    10.1002/cncr.29387. Epub 2015 Apr 14. PubMed [citation] PMID: 25872978
  13. Dotan E, Li T, Hall MJ, Meropol NJ, Beck JR, Wong YN. Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. J Oncol Pract. 2014 Sep;10(5):308-14. doi:
    10.1200/JOP.2014.001439. Epub 2014 Jul 22. PubMed [citation] PMID: 25052499,
    PMCID: PMC4161728
  14. Stump TK, Eghan N, Egleston BL, Hamilton O, Pirollo M, Schwartz JS, Armstrong K, Beck JR, Meropol NJ, Wong YN. Cost concerns of patients with cancer. J Oncol Pract. 2013 Sep;9(5):251-7. doi: 10.1200/JOP.2013.000929. Epub 2013 Jul 16.
    PubMed [citation] PMID: 23943901, PMCID: PMC3770507
  15. Wong YN, Egleston BL, Sachdeva K, Eghan N, Pirollo M, Stump TK, Beck JR, Armstrong K, Schwartz JS, Meropol NJ. Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care. 2013 Sep;51(9):838-45. doi: 10.1097/MLR.0b013e31829faffd. Erratum in: Med Care. 2013 Nov;51(11):1029. PubMed [citation] PMID: 23872905, PMCID: PMC3857689